Shares of the biotech were up 4.3% in premarket trading, after it also beat Wall Street expectations for second-quarter ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

This fall, it may not be possible for many parents to have a healthy child younger than age 5 immunized against COVID.

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

The federal government’s move to pull hundreds of millions of dollars in funding for mRNA vaccines could be a shot in the arm ...

Novavax ( ($NVAX) ) has risen by 24.00%. Read on to learn why. Novavax has experienced a notable 24.00% increase in its stock price over the past ...

Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment ...

Discover Novavax's Q2 2025 earnings insights: raised revenue targets, cost reductions, key partnerships with Sanofi & Takeda, and progress in ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Novavax, with a price target of $8.00. The company’s shares closed yesterday at $7.58. Elevate ...

Novavax shares shot higher after the biotechnology company's second-quarter profit and revenue beat analyst expectations. Shares were up 15% at $7.73 on Wednesday. The stock is up 33% over the past ...